$0.97
2.02% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Stock price

$0.99
-0.04 3.88% 1M
-0.24 19.51% 6M
+0.08 8.79% YTD
+0.07 7.07% 1Y
-2.16 68.57% 3Y
-5.74 85.29% 5Y
-6.72 87.16% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.01 1.00%
ISIN
US23283X2062
Symbol
CTSO
Sector

Key metrics

Market capitalization $61.88m
Enterprise Value $80.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.26
P/S ratio (TTM) P/S ratio 1.74
P/B ratio (TTM) P/B ratio 4.89
Revenue growth (TTM) Revenue growth -2.08%
Revenue (TTM) Revenue $35.59m
EBIT (operating result TTM) EBIT $-19.05m
Free Cash Flow (TTM) Free Cash Flow $-14.71m
Cash position $8.28m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 1.42
EV/Sales forward 1.85
Short interest 3.03%
Show more

Is CytoSorbents Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

CytoSorbents Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

Buy
50%
Hold
50%

Financial data from CytoSorbents Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
36 36
2% 2%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
1% 1%
98%
- Research and Development Expense 6.92 6.92
56% 56%
19%
-17 -17
39% 39%
-49%
- Depreciation and Amortization 1.75 1.75
14% 14%
5%
EBIT (Operating Income) EBIT -19 -19
38% 38%
-54%
Net Profit -21 -21
27% 27%
-58%

In millions USD.

Don't miss a Thing! We will send you all news about CytoSorbents Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytoSorbents Corporation Stock News

Neutral
PRNewsWire
about 11 hours ago
PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Company's Rights Offering in January 2025.
Neutral
Seeking Alpha
4 days ago
Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H. C. Wainwright Thomas Kerr - Zacks Small Cap Research Operator Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Co...
Neutral
PRNewsWire
4 days ago
2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The ...
More CytoSorbents Corporation News

Company Profile

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Head office United States
CEO Phillip Chan
Employees 149
Founded 2002
Website cytosorbents.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today